Advanced Enzyme Technologies Limited has informed the Exchange that Board of Directors at its meeting held on May 13, 2025, recommended Final Dividend of Rs. 1.20 per equity share.
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.1 pts less than Nifty Microcap 250 and 3.4 pts less than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Advanced Enzyme Technologies met on May 13, 2025, and approved audited consolidated results for FY25. Revenue from operations rose to Rs. 6,369.10 million (vs Rs. 6,238.68 million in FY24), while net profit was Rs. 1,339.74 million (vs Rs. 1,369.51 million). The Board recommended a Final Dividend of Rs. 1.20 per share (60% on face value of Rs. 2) for FY25, subject to shareholder approval at the AGM on July 30, 2025. It also declared an Interim Dividend of Rs. 4 per share (200% on face value) for FY26, payable to shareholders on record as of May 17, 2025. Additionally, the Board approved incorporation of a new wholly-owned subsidiary in India and appointed Mr. Shiv Hari Jalan as Secretarial Auditor for 5 years. MSKA & Associates issued an unmodified audit opinion.
Shareholders will receive a total dividend of Rs. 5.20 per share for FY25-FY26 combined (Rs. 4 interim + Rs. 1.20 final), reflecting a strong payout despite a marginal dip in annual net profit. The ex-dividend record date of May 17, 2025 makes the stock attractive for income-focused investors in the near term, while the new subsidiary and clean audit opinion support operational stability.